Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Crescent Biopharma (CBIO) Research & Development (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Research & Development for 11 consecutive years, with $14776.0 as the latest value for Q1 2025.

  • On a quarterly basis, Research & Development fell 99.75% to $14776.0 in Q1 2025 year-over-year; TTM through Mar 2025 was $14.0 million, a 32.1% decrease, with the full-year FY2024 number at $14.3 million, down 28.96% from a year prior.
  • Research & Development was $14776.0 for Q1 2025 at Crescent Biopharma, down from $1.7 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $13.3 million in Q3 2021 to a low of $14776.0 in Q1 2025.
  • A 5-year average of $6.9 million and a median of $6.0 million in 2022 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: soared 54.34% in 2024, then plummeted 99.75% in 2025.
  • Crescent Biopharma's Research & Development stood at $12.9 million in 2021, then crashed by 54.32% to $5.9 million in 2022, then decreased by 10.23% to $5.3 million in 2023, then tumbled by 67.56% to $1.7 million in 2024, then tumbled by 99.14% to $14776.0 in 2025.
  • Per Business Quant, the three most recent readings for CBIO's Research & Development are $14776.0 (Q1 2025), $1.7 million (Q3 2024), and $6.3 million (Q2 2024).